Comparison 4. Oestrogen + other treatments versus oestrogen.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number with incontinence not improved (women's observations)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
1.1 Oestrogen + PPA vs oestrogen	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Number with incontinence not improved (women's observations) (cross‐over trials)			Other data	No numeric data
2.1 oestrogen + PPA vs oestrogen			Other data	No numeric data
3 Number of pad changes over 24 hours	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3.1 oestrogen + PPA vs oestrogen	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Number of voids over 24 hours	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 oestrogen + PPA vs oestrogen	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Pad test weights	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5.1 oestrogen + PPA vs oestrogen	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Number of women with frequency	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
6.1 oestriol + benzidamine vs oestriol	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Number of women with nocturia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7.1 oestriol + benzidamine vs oestriol	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
8 Number with adverse effects	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
8.1 Oestrogen + PPA vs oestrogen	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
9 Volume at first urge to void (cross‐over trials)			Other data	No numeric data
9.1 oestrogen + PPA vs oestrogen			Other data	No numeric data
10 Maximum bladder capacity (cross‐over trials)			Other data	No numeric data
10.1 oestrogen +other vs oestrogen			Other data	No numeric data